About Us

Vésale Group

A pioneer in the field of probiotic solutions, Vésale Pharma is a Walloon company that has been marketing probiotic specialties for more than 15 years based on the latest scientific discoveries. Vésale Pharma markets a very wide range of products targeting the digestive sphere, the pediatric sphere and women’s health. Its products are currently marketed in Europe, Asia and the Middle East via a network of distributors and in Belux via pharmacies. Vésale Pharma places innovation at the heart of its activities and devotes 23% of its turnover to R&D activities with an internal staff of 7 people. Vésale collaborates with research centers in Belgium and abroad.

1996

creation

Vésale Pharma is born

1996
2012

Intelicaps®

In 2012, Vésale Pharma patented a micro-encapsulation process for probiotics (Intelicaps®) which protects probiotics from humidity and heat. The process also protects bacteria from gastric acid and pancreatic juice without altering their functionality.

2012
2016

Development in Ghlin

In June 2016, Vésale Pharma inaugurated a new production unit coupled with its R&D activities in Ghlin.

2016
2017

Wagralim PorcBiota

(Pôle Wagralim)

2017
2018

Phages

Creation of Vésale Bioscience, a spin-out from Vésale Pharma dedicated to phagotherapy

https://phage.health/

2018
2018

Project SUNUP

(Pôle Wagralim)

2018
2022

Probiotics

In 2022, Vésale Pharma will continues its research activities along 3 ranges (Women Health, Digestive and Pediatric) to bring new products to market from 2022.

2022

Commercial strategy based on R&D

Vésale Pharma therefore relies on the development of innovative products to remain competitive. The products marketed by Vésale Pharma have the following characteristics:

  • They contain living probiotics that is to say, exerting a metabolic activity
  • The strains are scientifically documented. For each strain Vésale has established a monograph bringing together several relevant scientific publications demonstrating the benefits of said strains
  • The strains show resistance to gastric acidity and bile salts preserving their functional capacity up to the intestinal site thanks to the Intelicaps encapsulation process
  • They target various spheres: digestive health, women’s health and immunity (for this last target the commercialization is planned for 2022)
  • They are shaped in the form of semi-finished products: premix or finished: formulations in standardized form or custom (personalized/tailor made)
 

Unlike large probiotic solution providers Vésale has the flexibility (“agility”) to quickly adapt the composition and galenic of its products (capsules, sachets, oro-soluble powder, tablets, tablets, chewable tablets or form liquid in order to allow their administration to each member of the family (including the pregnant woman).

Our Team

Meet our team

Jehan LIENART

CEO

Eric POSKIN

Spokesman

Jacqueline ABRASSART

Finance & Admin Director

Charlotte LIENART

BELUX Sales Manager

Titouan VESTERS

Operations Manager & Global Marketing Director

Marleen Van D'huynslager

International Sales Director

France FANNES

Collaborations & Corporate Compliance Director

Serge LOCQUET

BELUX Business Development Manager